Aug. 19 at 6:59 AM
$OTLK $COR
$OTLK Q3 10-Q + earnings call: the setup for Q4/Q1
FDA approval is done, and
$OTLK targets U.S. launch before year-end 2026. The company raised ~
$51.1M net to support commercialization.
Launch readiness:
• ~
$5.04M inventory
• ~
$2.51M WIP, +162% vs. Sept.
• Management says supply is sufficient for launch
• U.S. manufacturing + distribution infrastructure
• ~30 commercial + ~20 reimbursement specialists planned
• European units +46% QoQ
• Adjusted net loss down ~31% YoY
Management's first-12-month U.S. net-revenue outlook is
$50–75M, with >
$500M annual U.S. sales as its base case before 2030.
Launch ramps gradually: ~10% of first-year revenue in the first 3 months, accelerating toward ~50% by Q4.
Q4 = launch execution. Q1 FY2027 = the real test: U.S. units, sell-through, reorders and revenue.
The pieces are in place. Now we watch execution.
Looks really good!
